# Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers

> **NCT03077477** · PHASE1 · WITHDRAWN · sponsor: **Aminex Therapeutics, Inc.**

## Conditions studied

- Neoplasms
- Medication Toxicity
- Tolerance

## Interventions

- **DRUG:** AMXT 1501
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03077477
- **Lead sponsor:** Aminex Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-06-12
- **Primary completion:** 2018-06-12
- **Final completion:** 2018-06-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Change in FDA required patient population decision prior to study start, new protocol developed, this protocol withdrawn
- **Last updated:** 2018-06-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03077477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03077477, "Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03077477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*